Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO

SECTION 13 or 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

                    December 20, 2013                    

Date of Report (Date of earliest event reported)

    INVIVO THERAPEUTICS HOLDINGS CORP.    

(Exact Name of Registrant as Specified in Charter)

 

NEVADA

  

000-52089

  

36-4528166

(State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)

One Kendall Square, Suite B14402

            Cambridge, Massachusetts 02139            

(Address of Principal Executive Offices) (Zip Code)

            (617) 863-5500            

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

On December 20, 2013, the Food and Drug Administration informed InVivo Therapeutics Holdings Corp. (the “Company”) that the Company should expect the agency’s response to the Company’s November 22, 2013 protocol amendments during the week of December 23, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    INVIVO THERAPEUTICS HOLDINGS CORP.
Date: December 20, 2013     By:   /s/ Michael J. Astrue
     

Michael J. Astrue

Interim Chief Executive Officer